Alterity Therapeutics

DR DAVID STAMLER

CEO

(ASX:ATH)

◾ Company Name: Alterity Therapeutics ◾ Company ASX code: ATH, NASDAQ: ATHE ◾ Key areas: Developing first-in-class therapies to treat neurodegenerative diseases, with a special focus on parkinsonian disorders ◾ Key Personnel: Dr David Stamler, CEO | Kathryn Andrews, CFO | Geoffrey Kempler, Chairman and Founder ◾ Locations: Melbourne and San Francisco, United States ◾ Market Cap as of 15/09/22: $36.10M ◾ 52 Week share price as of 15 September: $0.013 - $0.033 ◾ Company Website: alteritytherapeutics.com

COMPANY PROFILE

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases.

The company is focused on Parkinson’s disease and related disorders where there is a high unmet medical need.

While available therapies address the symptoms of these disorders, Alterity is targeting the underlying pathology of the disease. The company’s lead drug candidate, ATH434, is designed to inhibit the aggregation of alpha-synuclein, a protein implicated in neurodegeneration, preserve nerve cells, and improve function by restoring normal iron balance in the brain.

Through this mechanism it has excellent potential to treat Parkinson’s disease as well as less common Parkinsonian disorders such as Multiple System Atrophy (MSA).

MSA is a rare, degenerative neurological disease characterized by failure of the involuntary (autonomic) nervous system and impaired movement that affects up to five out of every 100,000 people globally. It is a rapidly progressive disease and causes profound disability.

Alterity’s lead program could be the first approved treatment for MSA that is neuroprotective, meaning it preserves nerve cells, maintains function and slows the progression of disease.

Alterity has received Orphan Drug designation for ATH434 in MSA in the US and EU which provides market exclusivity for several years after approval.

The company is currently enrolling MSA patients in its global Phase 2 clinical trial evaluating the effect of ATH434 on MRI endpoints and protein biomarkers, such as aggregating alpha-synuclein. A prior Phase 1 study has found the molecule to be safe and well-tolerated.

The first Phase 2 patient was enrolled in New Zealand and study was recently launched in the United Kingdom. Alterity plans to expand the trial to other regions including Australia, the US, and other European countries by the end of the year.

Alterity also has a broad R&D pipeline that includes a natural history study in MSA designed to de-risk the Phase 2 trial, preclinical studies to optimize dosing of ATH434 for Parkinson’s disease, and a strong drug discovery and research arm.

The company holds a strong intellectual property portfolio, with over 800 validated compounds from its chemical library. Alterity was recently granted new US patents covering 230 novel compounds as next generation therapies targeting major neurodegenerative diseases. Alterity is led by a team with deep R&D experience that includes three drug approvals by the US FDA.

Alterity was incorporated in Melbourne, Australia in 1997 as Prana Biotechnology. The company listed on the Australian Securities Exchange in 2000 and Nasdaq in 2002, changing its name in 2019.

Alterity has a strong leadership team with Dr David Stamler appointed CEO in January 2021. He previously served as the company’s chief medical officer and senior vice president, clinical development since 2017.

Stamler has vast experience in the development of pharmaceuticals, beginning his career at Abbott Laboratories.

He held senior positions at Teva Pharmaceutical Industries after it acquired Auspex Pharmaceuticals for $US 3.5 billion, where he served as CMO. He also held senior positions at XenoPort, Prestwick Pharmaceuticals, and Fujisawa Pharmaceutical Co and its subsidiaries.

Founder Geoffrey Kempler has served as chairman of the Board of Directors since November 1997. He was CEO from November 1997 until August 2004 and assumed the position again from June 2005 until January 2021.

Kempler has extensive experience in investment and business development and has been responsible for the implementation of the Company’s strategic plan.

KEY INVESTMENT HIGHLIGHTS

JUNE 23, 2022: The Italian Medicines Agency granted regulatory authorization for Alterity to conduct its Phase 2 trial. JULY 6, 2022: The first patient dosed in Alterity’s Phase 2 clinical trial of ATH434 in MSA. AUGUST 25, 2022: Alterity announces the UK launch of its Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare Parkinsonian disorder.